Relationship of microparticles to progenitor cells as a measure of vascular health in a diabetic population

Cytometry Part B - Clinical Cytometry

Volumn 78, Issue 5, 2010, Pages 329-337

  Curtis, Anne M ^a,b   Zhang, Lifeng ^c   Medenilla, Elizabeth ^c   Gui, Ming ^b   Wilkinson, Patrick F ^a   Hu, Erding ^b   Giri, Jay ^c   Doraiswamy, Vijay ^c   Gunda, Sampath ^c   Burgert, Mark E ^b   Moore, Jonni S ^c   Edelberg, Jay M ^b   Mohler III, Emile R ^c  

^a SCIENCE FOUNDATION IRELAND   (Ireland)

^b GLAXOSMITHKLINE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Diabetes; Endothelial; Microparticles; Progenitor; Vascular

Indexed keywords

C REACTIVE PROTEIN; CD133 ANTIGEN; CD34 ANTIGEN; CELL SURFACE MARKER; ERYTHROPOIETIN; FIBRINOGEN RECEPTOR; HEMOGLOBIN A1C; INTERCELLULAR ADHESION MOLECULE 1; LIPOCORTIN 5; PHOSPHATIDYLSERINE; VASCULAR CELL ADHESION MOLECULE 1; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN RECEPTOR 2; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; BIOLOGICAL MARKER; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; PLASMINOGEN ACTIVATOR INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; APOPTOSIS; ARTICLE; CARDIOVASCULAR RISK; CELL DAMAGE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL MICROPARTICLE; ENDOTHELIAL PROGENITOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; MALE; MEMBRANE VESICLE; NON INSULIN DEPENDENT DIABETES MELLITUS; PLATELET MICROPARTICLE; PRIORITY JOURNAL; STEM CELL; BLOOD; BLOOD PRESSURE; COHORT ANALYSIS; DIABETIC ANGIOPATHY; DRUG EFFECT; MEMBRANE MICROPARTICLE; METABOLISM; MIDDLE AGED; PATHOLOGY; VASCULAR ENDOTHELIUM; BLOOD CELL COUNT; BLOOD SAMPLING; CARDIOVASCULAR FUNCTION; CD34 SELECTION; CELL ISOLATION; CHOLESTEROL BLOOD LEVEL; DIABETIC PATIENT; HEALTH STATUS; LEUKOCYTE COUNT;

ADULT; AGED; ANTIGENS, CD34; BLOOD PRESSURE; CELL-DERIVED MICROPARTICLES; CHOLESTEROL; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; STEM CELLS;

EID: 77956567491     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.20528     Document Type: Article

References (42)

1. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA 1979;241:2035-2038.
2. Kuvin JT, Patel AR, Sliney KA, Pandian NG, Rand WM, Udelson JE, Karas RH. Peripheral vascular endothelial function testing as a noninvasive indicator of coronary artery disease. J Am Coll Cardiol 2001;38:1843-1849.
3. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: A comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001;285:2481-2485. (Pubitemid 32433842)
4. Koga H, Sugiyama S, Kugiyama K, Watanabe K, Fukushima H, Tanaka T, Sakamoto T, Yoshimura M, Jinnouchi H, Ogawa H. Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2005;45:1622-1630. (Pubitemid 40704497)
5. Shaffer RG, Greene S, Arshi A, Supple G, Bantly A, Moore JS, Mohler ER III. Flow cytometric measurement of circulating endothelial cells: The effect of age and peripheral arterial disease on baseline levels of mature and progenitor populations. Cytometry B Clin Cytom 2006;70B:56-62.
6. Mohler ER III, Shi Y, Moore J, Bantly A, Hamamdzic D, Yoder M, Rader DJ, Putt M, Zhang L, Parmacek M, Wilensky RL. Diabetes reduces bone marrow and circulating porcine endothelial progenitor cells, an effect ameliorated by atorvastatin and independent of cholesterol. Cytometry A 2009;75A:75-82.
7. Möbius-Winkler S, Höllriegel R, Schuler G, Adams V. Endothelial progenitor cells: Implications for cardiovascular disease. Cytometry A 2009;75A:25-37.
8. Martinez MC, Tesse A, Zobairi F, Andriantsitohaina R. Shed membrane microparticles from circulating and vascular cells in regulating vascular function. Am J Physiol Heart Circ Physiol 2005; 288:H1004-H1009. (Pubitemid 40269999)
9. Deregibus MC, Cantaluppi V, Calogero R, Lo Iacono M, Tetta C, Biancone L, Bruno S, Bussolati B, Camussi G. Endothelial progenitor cell derived microvesicles activate an angiogenic program in endothelial cells by a horizontal transfer of mRNA. Blood 2007; 110:2440-2448.
10. Morel O, Toti F, Hugel B, Bakouboula B, Camoin-Jau L, Dignat-George F, Freyssinet JM. Procoagulant microparticles: Disrupting the vascular homeostasis equation? Arterioscler Thromb Vasc Biol 2006;26:2594-2604.
11. Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E, Celi A, Croce K, Furie BC, Furie B. Accumulation of tissue factor into developing thrombi in vivo is dependent upon microparticle Pselectin glycoprotein ligand 1 and platelet P-selectin. J Exp Med 2003;197:1585-1598.
12. Barry OP, Pratico D, Lawson JA, FitzGerald GA. Transcellular activation of platelets and endothelial cells by bioactive lipids in platelet microparticles. J Clin Invest 1997;99:2118-2127.
13. Boulanger CM, Scoazec A, Ebrahimian T, Henry P, Mathieu E, Tedgui A, Mallat Z. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation 2001;104: 2649-2652.
14. Morel O, Ohlmann P, Epailly E, Bakouboula B, Zobairi F, Jesel L, Meyer N, Chenard MP, Freyssinet JM, Bareiss P, Mazzucotelli JP, Toti F. Endothelial cell activation contributes to the release of procoagulant microparticles during acute cardiac allograft rejection. J Heart Lung Transplant 2008;27:38-45.
15. Matsumoto N, Nomura S, Kamihata H, Kimura Y, Iwasaka T. Increased level of oxidized LDL-dependent monocyte-derived microparticles in acute coronary syndrome. Thromb Haemost 2004;91: 146-154.
16. Amabile N, Guerin AP, Leroyer A, Mallat Z, Nguyen C, Boddaert J, London GM, Tedgui A, Boulanger CM. Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol 2005;16:3381-3388.
17. Nozaki T, Sugiyama S, Koga H, Sugamura K, Ohba K, Matsuzawa Y, Sumida H, Matsui K, Jinnouchi H, Ogawa H. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. J Am Coll Cardiol 2009;54: 601-608.
18. Boulanger CM, Amabile N, Tedgui A. Circulating microparticles: A potential prognostic marker for atherosclerotic vascular disease. Hypertension 2006;48:180-186.
19. Curtis AM, Wilkinson PF, Gui M, Gales TL, Hu E, Edelberg JM. p38 mitogen-activated protein kinase targets the production of proinflammatory endothelial microparticles. J Thromb Haemost 2009;7: 701-709.
20. Nomura S, Shouzu A, Omoto S, Nishikawa M, Iwasaka T. Effects of losartan and simvastatin on monocyte-derived microparticles in hypertensive patients with and without type 2 diabetes mellitus. Clin Appl Thromb Hemost 2004;10:133-141.
21. Pirro M, Bagaglia F, Paoletti L, Razzi R, Mannarino MR. Hypercholesterolemia- associated endothelial progenitor cell dysfunction. Ther Adv Cardiovasc Dis 2008;2:329-339.
22. Pirro M, Schillaci G, Paltriccia R, Bagaglia F, Menecali C, Mannarino MR, Capanni M, Velardi A, Mannarino E. Increased ratio of CD31+/CD42- microparticles to endothelial progenitors as a novel marker of atherosclerosis in hypercholesterolemia. Arterioscler Thromb Vasc Biol 2006;26:2530-2535.
23. Spijkerman AM, Dekker JM, Nijpels G, Jager A, Kostense PJ, van Hinsbergh VW, Bouter LM, Heine RJ, Stehouwer CD. Impact of diabetes duration and cardiovascular risk factors on mortality in type 2 diabetes: The Hoorn Study. Eur J Clin Invest 2002;32:924-930.
24. Friedewald WT, Levy RI, Frederickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without the use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
25. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234.
26. Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Heller GV, Iskandrian AE, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE; DIAD Investigators. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: The DIAD study: A randomized controlled trial. JAMA 2009; 301:1547-1555.
27. Leroyer AS, Tedgui A, Boulanger CM. Role of microparticles in atherothrombosis. J Intern Med 2008;263:528-537.
28. Bernal-Mizrachi L, Jy W, Fierro C, Macdonough R, Velazques HA, Purow J, Jimenez JJ, Horstman LL, Ferreira A, de Marchena E, Ahn YS. Endothelial microparticles correlate with high-risk angiographic lesions in acute coronary syndromes. Int J Cardiol 2004;97:439-446.
29. Nomura S, Ozaki Y, Ikeda Y. Function and role of microparticles in various clinical settings. Thromb Res 2008;123:8-23.
30. Wang JM, Huang YJ, Wang Y, Xu MG, Wang LC, Wang SM, Tao J. Increased circulating CD31+/CD42- microparticles are associated with impaired systemic artery elasticity in healthy subjects. Am J Hypertens 2007;20:957-964.
31. Wang JM, Wang Y, Huang JY, Yang Z, Chen L, Wang LC, Tang AL, Lou ZF, Tao J. C-Reactive protein-induced endothelial microparticle generation in HUVECs is related to BH4-dependent NO formation. J Vasc Res 2007;44:241-248.
32. Brodsky SV, Zhang F, Nasjletti A, Goligorsky MS Endothelium-derived microparticles impair endothelial function in vitro. Am J Physiol Heart Circ Physiol 2004;286:H1910-H1915.
33. Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S, Iwasaka T. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res 2006;117:385-392.
34. Sommeijer DW, Joop K, Leyte A, Reitsma PH, ten Cate H. Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derived microparticles in patients with type 2 diabetes. J Thromb Haemost 2005;3: 1168-1171.
35. Hill JM, Zalos G, Halcox JP, Schenke WH, Waclawiw MA, Quyyumi AA, Finkel T. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348:593-600.
36. Fadini GP, Sartore S, Agostini C, Avogaro A. Significance of endothelial progenitor cells in subjects with diabetes. Diabetes Care 2007; 30:1305-1313. (Pubitemid 46684670)
37. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003;102:1340-1346.
38. Bahlmann FH, de GK, Spandau JM, Landry AL, Hertel B, Duckert T, Boehm SM, Menne J, Haller H, Fliser D. Erythropoietin regulates endothelial progenitor cells. Blood 2004;103:921-926.
39. Bruno CM, Sciacca C, Bertino G, Cilio D, Pellicano R, Marchese AE, Politi G, Chinnici L. Circulating erythropoietin in microalbuminuric type 2 diabetic patients with normal renal function: A pilot study. J Diabetes Complications 2006;20:376-379.
40. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rutten H, Fichtlscherer S, Martin H, Zeiher AM. HMGCoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001;108:391-397.
41. Boulanger CM, Amabile N, Guerin AP, Pannier B, Leroyer AS, Mallat CN, Tedgui A, London GM. In vivo shear stress determines circulating levels of endothelial microparticles in end-stage renal disease. Hypertension 2007;49:902-908.
42. Leroyer AS, Isobe H, Leseche G, Castier Y, Wassef M, Mallat Z, Binder BR, Tedgui A, Boulanger CM. Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. J Am Coll Cardiol 2007;49:772-777.